Imperial Innovations Group has appointed Dr Paolo Paoletti as executive chairman of portfolio company Kesios Therapeutics.
Paoletti was formerly the first appointed president of GSK Oncology, where he was responsible for the overall oncology business within the firm and oversaw activities from early drug discovery through to clinical development, launch and life cycle management.
Commenting on his appointment, Paoletti said: “I’m extremely pleased to take this role to accelerate the clinical development of this new molecule and, hopefully, to translate the very innovative and interesting pre-clinical science in an impactful medicine for patients affected by multiple myeloma and other forms of cancer.”
Paoletti is additionally a non-executive director of PsiOxus Therapeutics, Innovation’s sixth largest portfolio company, which is developing innovative immune-oncology treatments for cancer.
Maina Bhaman, director of healthcare ventures at Imperial Innovations, said: “We are delighted that Paolo has agreed to join Kesios as Executive Chairman. He brings a wealth of industry experience, which has already proved to be invaluable to PsiOxus and no doubt will help the Kesios team to accelerate the development of their programme.
“The fact that we are able to attract such experienced individuals to our portfolio, speaks volumes about the quality of the science we are commercialising and our philosophy of putting together world class management with world class science.”
Kesios, which is based in Kensington, London, was created to develop and commercialise research from the Department of Medicine at Imperial College London.